Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results

Pharmaceutical Investing

Catalyst Biosciences (NASDAQ:CBIO) announced operating and financial results for the fourth quarter and full-year ended December 31, 2017 and provided a corporate update. As quoted in the press release: “2017 was a pivotal year for us as we continued to make significant progress in the clinical development of both of our subcutaneously administered next-generation subcutaneously …

Catalyst Biosciences (NASDAQ:CBIO) announced operating and financial results for the fourth quarter and full-year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

“2017 was a pivotal year for us as we continued to make significant progress in the clinical development of both of our subcutaneously administered next-generation subcutaneously dosed, FIX and FVIIa, coagulation factors,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “With our recent equity offering, our balance sheet provides the resources to further accelerate the clinical development programs of our Factor IX and VIIa candidates through multiple key milestones in 2018 and 2019.”

Click here to read the full press release.

biosciences candidates coagulation corporate update financial results key milestones us Pharmaceutical Investing